Drawing for DELEVA

USPTO serial 87077151

DELEVA

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
BULLOFF, TOBY ELLEN
Law office
TMO LAW OFFICE 119 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with DELEVA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of a coating for VITAMINS that facilitate the delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of a coating for DRUGS that facilitate the delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of PATCHES that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of TABLETS that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of CAPSULES that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of LIQUID DISPERSIONS that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of PELLETS that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of PARTICLES that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of POWDER that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of COATINGS that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of GRANULES that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of INSERTS that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of STENTS that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of TUBE that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of ROD that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of FILMS that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of SOLUTIONS that facilitate the delivery of pharmaceutical preparations; Implantable subcutaneous drug delivery devices sold filled with pharmaceutical preparations for CONTROLLED RELEASE OF DRUG; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Transdermal patches featuring VITAMINS FOR PROMOTING GOOD HEALTHACTIVE—
010Drug delivery systems; Implantable subcutaneous drug delivery devices sold emptyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Nov 2, 2017MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Nov 2, 2017ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Apr 5, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 5, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 5, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 21, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 20, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 20, 2017ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Oct 28, 2016GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Oct 28, 2016GNSLLETTER OF SUSPENSION E-MAILED—
Oct 28, 2016CNSLSUSPENSION LETTER WRITTEN—
Oct 19, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 19, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 14, 2016ALIEASSIGNED TO LIE—
Oct 4, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 4, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 4, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 4, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 27, 2016DOCKASSIGNED TO EXAMINER—
Jun 24, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 23, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance